The global POC and rapid diagnostics market is expected to reach $ 72.0 billion in 2027 from an estimated $ 43.2 billion in 2022, with a CAGR of 10.8% from 2022 to 2027. The growth of the global Point of The market for diagnostic care can be attributed to factors such as the growing prevalence of respiratory diseases (such as COVID-19 and influenza) worldwide, and better prevalence of access to on-site facilities through online platforms are some of the other important factors likely. . drives long-term growth in the care diagnostics market.


Impact of COVID-19 on the global Point of Care market
The COVID-19 epidemic has accelerated the global demand for diagnostic kits for rapid disease detection. However, countries worldwide are facing a serious shortage of laboratory molecular tests. Many players are therefore looking to expand the range of trials worldwide. The medical diagnostics market will see significant growth in 2022 due to the increased use of POC tests that can easily diagnose COVID-19. The need for rapid diagnostic results makes healthcare point testing an important diagnostic tool. The rapid increase in COVID-19 cases and increasing pressure on governments to improve patient care have increased the need for rapid antigen testing kits that can be used effectively in institutional settings.

Others include the growing prevalence of other respiratory diseases worldwide, the transition to decentralized diagnosis and better access to on-site facilities through online platforms. -fan. – the market for diagnostic care.

Point of Care market dynamics
Driver: High prevalence of infectious diseases
POC testing can improve the treatment of infectious diseases, especially in developing countries, where access to early medical care is a problem and medical infrastructure is a problem. Healthcare is old and small. According to UNAIDS, by 2018, there will be almost 20.6 million people living with HIV in East and South Africa. By 2019, 20,000 new HIV cases will be registered in the Middle East and North Africa (Source: UNAIDS Data 2020). It is estimated that in 2019, 5.8 million people in Asia-Pacific will be infected with HIV, leading to India and China. According to UNAIDS, an estimated 2.1 million people in India will be infected with HIV in 2019.

According to the WHO, India is the biggest burden of tuberculosis, with an estimated incidence of 2.64 million cases in 2020.
In 2019, approximately 4.3 million new tuberculosis cases were reported in Southeast Asia, and 632,000 people in the area died of TB infections (Source: WHO).
According to the National Influenza Policy 2017, about 10,000 people die each year in South Africa, and 40,000 are hospitalized for the flu.


The epidemic resulted in more than 28,600 cases and 11,325 deaths. It is estimated that 15,898 people in Brazil will be at risk from the Zika virus by 2020, an increase of more than 30,000 cases reported last year.
The high prevalence of infectious diseases, combined with the lack of equipment for health care infrastructure in developing countries, is expected to pressure the adoption of POC tests.


Leading companies and market share statistics
On-site diagnostics have shown significant improvement in recent years. Integrating molecular diagnostics with POC tests is one of the important advances in this field. Even though large players have limited opportunities for new entrants, some companies have been able to mark their entry into the market. In addition, leading companies are developing more sophisticated desktop and portable test solutions to keep the market competitive. For example, in March 2022, First Health announced that it would enter into a partnership with Siemens Healthineers to expand the Atellica VTLi Patient Site Immunoassay Analyzer distribution channel in the United Kingdom.


The product launch demonstrates the company’s commitment to POC diagnostics and critical care. In March 2022, Visby Medical announced that it would receive $ 25.5 million from the U.S. Department of Advanced Biomedical Research to conduct rapid PCR testing of COVID-19 influenza for home use. The test is currently under development, and a design is being prepared as a PCR device that can detect COVID-19, influenza A and B from a single sample.


Aslo Read: neuroendoscopy market